Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Abstract: Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The antibody molecules can be used to treat or prevent cancerous or infectious conditions and disorders.

Abstract: The present invention relates to tumor targeted superagonistic antigen binding molecules capable of multivalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

Abstract: The present invention relates to compositions and methods of treating multiple sclerosis. Particularly, the present invention relates to pharmaceutical compositions comprising antibodies having affinity to both fibroblast growth factor receptor 2 (FGFR2) and FGFR3 for use in treating multiple sclerosis.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.

Abstract: Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, recombinant antibodies are disclosed that are able to engage T-cells to destroy CD123-expressing malignant cells.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Anti-CD40L antibodies and antigen binding fragments thereof, compositions comprising the antibodies or antigen binding fragments, Anti-CD40L antibodies with reduced effector function, and method of using same for treatment of CD40L-related diseases or disorders.

Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.

Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Abstract: The present invention relates to combination therapies with anti-CD38 antibodies.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: The present invention relates to a polypeptide including an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The present invention also relates to an antibody including the polypeptide. The Fc variant can find application in a wide range of antibodies and Fc-fusion constructs. In one aspect, the antibody or Fc fusion construct of the present invention is a therapeutic, diagnostic or laboratory reagent, preferably a therapeutic reagent. The Fc variant is suitable for use in the treatment of cancer because its in vivo half-life can be maximized by optimization of the portion of the amino acid sequence. The antibody or Fc fusion construct of the present invention is used to kill target cells that bear a target antigen, for example cancer cells. Alternatively, the antibody or Fc fusion construct of the present invention is used to block, antagonize or agonize a target antigen.

Abstract: Multispecific antibody analogs that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), said analogs comprising a common light chain, are provided, as well as methods for their production and use.

Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.

Abstract: Provided is a pharmaceutical composition comprising a PCSK9 antibody or an antigen-binding fragment thereof in a histidine buffer. In addition, the pharmaceutical composition may also comprise saccharides and nonionic surfactants.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: The invention discloses a brand-new PCSK9 antibody. The PCSK9 antibody is sieved through a phage display technology, then a full-length gene sequence is obtained through a gene engineering technology, and applied to preparation of the antibody, and the prepared antibody is high in yield and short in period and is a humanized antibody. The invention further discloses an anti-tumor effect of the antihuman PCSK9 antibody, which expands the way of thinking for research on occurrence and development of tumors in the future, and lays foundations for preparing the antihuman PCSK9 antibody into monoclonal antibody medicines used for treating tumors in the later period.

Abstract: The present disclosure provides humanized antibodies, including antibodies comprising an ultralong CDR3 and uses thereof.

Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.

Abstract: Regioselectively substituted cellulose esters having a plurality of pivaloyl substituents and a plurality of aryl-acyl substituents are disclosed along with methods for making the same. Such cellulose esters may be suitable for use in films, such as +A optical films, and/or +C optical films. Optical films prepared employing such cellulose esters have a variety of commercial applications, such as, for example, as compensation films in liquid crystal displays and/or waveplates in creating circular polarized light used in 3-D technology.

Abstract: Disclosed herein is a method of assessing rheology characteristics of vital wheat gluten to determine how to improve the quality of VWG product and the choice of VWG for a particular product.

Abstract: The present application relates to polymer microparticle-metal nanoparticle composites, to methods of preparing polymer microparticle-metal nanoparticle composites and to uses of such composites. The methods comprise introducing into a microfluidic device, a composition comprising: a cationic metal nanoparticle precursor; a polymer microparticle precursor that comprises a plurality of photopolymerizable groups; and a photoreducer-photoinitiator; then irradiating the composition under conditions to simultaneously reduce the cationic metal and polymerize the photopolymerizable groups to obtain the composite.

Abstract: A method for manufacturing a polymer by performing an anionic polymerization reaction by a flow-type reaction, including: introducing a liquid A containing an anionic polymerizable monomer, a liquid B containing an anionic polymerization initiator, and a polymerization terminator into different flow paths respectively and causing the liquids to flow in the respective flow paths; causing the liquid A and the liquid B to join together by using a multilayered cylindrical mixer; subjecting the anionic polymerizable monomer to anionic polymerization while a solution formed by the joining is flowing to downstream in the reaction flow path; and causing a polymerization reaction solution flowing in a reaction flow path and the polymerization terminator to join together such that the polymerization reaction is terminated; and a flow-type reaction system suitable for performing the manufacturing method.

Abstract: Methods for the production of heterophasic polymers in gas and slurry phase polymerization processes, and polymer compositions made therefrom, are disclosed herein.

Abstract: Processes are provided which include copolymerization using two different metallocene catalysts, one capable of producing high Mooney-viscosity polymers and one suitable for producing lower Mooney-viscosity polymers having at least a portion of vinyl terminations. The two catalysts may be used together in polymerization to produce copolymer compositions of particularly well-tuned properties. For instance, polymerizations are contemplated to produce high-Mooney metallocene polymers that exhibit excellent processability and elasticity, notwithstanding their high Mooney viscosity. Other polymerizations are also contemplated in which lower-Mooney metallocene polymers are produced, which also exhibit excellent processability and elasticity, while furthermore having excellent cure properties suitable in curable elastomer compound applications.

Abstract: A catalyst composition for selectively hydrogenating a conjugated diene polymer in a homogeneous system is provided, wherein the conjugated diene polymer comprises a conjugated diene monomer or a combination of a conjugated diene monomer and a vinyl aromatic monomer. The catalyst composition includes the catalyst components of (a) a titanium compound; (b) an organometallic compound; and (c) an oligomer containing a polyglycol segment. The hydrogenated polymer produced using the catalyst composition and the method thereof is also provided.

Abstract: A method for making a polymer, having the steps of (a) polymerizing one or more monomers in the presence of a solvent and a catalyst to form a reaction product; (b) removing an effluent from the reaction product, where the effluent comprises an active catalyst and one or more unreacted monomers; (c) combining a quench, comprising carbon dioxide, with the effluent to form a quenched polymer stream, having a carboxyl metal complex; and (d) recovering a polymer from the quenched polymer stream.

Abstract: This invention relates to a hydrogenated hydrocarbon resin and a method of preparing the same, wherein the preparation process is simplified, material supply problems can be solved, and the hydrogenated hydrocarbon resin can be prepared using a catalyst, which is inexpensive, has a low odor and is easy to handle, thereby realizing a yield and a preparation process that enable real-world application thereof. The hydrogenated hydrocarbon resin prepared by the method of the invention has excellent compatibility and a low specific viscosity, and can thus be efficiently used as a tackifier or an adhesive in a variety of fields.

Abstract: A halogenated polyisoolefin copolymer is composed of at least one isoolefin monomer, at least one multiolefin monomer, a halogen content of 0.05-2.5 mol %, and a halogenated oligomer content of less than 65% of total oligomer content in the halogenated polyisoolefin copolymer. The copolymer has low halogen content and significantly reduced levels of halogenated oligomers. The copolymer is especially useful in the pharmaceutical and food industries, for example as pharmaceutical and food product seals and closures.

Abstract: A process for enhancing the melt strength of polypropylene by extruding said polypropylene in a twin-screw extruder, under inert atmosphere, at a temperature between about 150° C. and about 300° C., and in the presence of about 0.1 to about 3.0 wt %, based on the weight of the polypropylene, of a para-substituted dibenzoyl peroxide.

Abstract: A method for encapsulating a catalyst in a dispersed polymer particle comprising dissolving a Group 8 to Group 11 transition metal containing catalyst and a self-dispersing polymer in a solvent; adding water and optionally a base under particle forming conditions to form a dispersed polymer encapsulated catalyst comprising particles having a population number average diameter between 10 and 300 nanometers is provided.

Abstract: A solid catalyst component for use in olefinic polymerization, includes titanium, magnesium, a halogen, and an internal electron donor compound; wherein: the internal electron donor compound is at least one compound represented by Formula (I)):

Abstract: A method of making a pyranine monomer composition comprises the step of reacting pyranine with a functionalizing agent that functionalizes the pyranine molecule with a polymerizable functional group to provide a composition of functionalized pyranine monomers, said functionalization reaction taking place in an aqueous reaction medium, and in the presence of a molar excess of said functionalizing agent, such that the functionalization reaction product is a monomer composition substantially free of unfunctionalized pyranine compound. The pyranine monomer compositions made by the method can be used to make fluorescent tagged water soluble polymer compositions that advantageously are substantially free of unpolymerized pyranine. The fluorescent tagged water soluble polymer compositions can be used in a method of inhibiting scale in industrial water systems.

Abstract: Provided is a method for preparing a conjugated diene-based copolymer, a conjugated diene-based copolymer prepared therefrom, and a rubber composition including the same.

Abstract: Provide is a polymer having a narrow molecular weight distribution by living radical polymerization. A polymer manufacturing method comprising a step of performing living radical polymerization using 0.005 to 0.5 parts by mass of an oxygen radical scavenger per 100 parts by mass of a radical polymerizable monomer.

Abstract: The present disclosure relates to a polypropylene for injection having a high content of ultra-high molecular weight and excellent rigidity, and a method for preparing the same.

Abstract: A method for forming polar-functionalized polyolefins may comprise contacting an unsubstituted ?-olefin monomer and an amino-olefin monomer of formula H2C?CH(CH2)n(CHR)mNR?2, wherein R is H or an unsubstituted linear or branched alkyl group having from 1 to 10 carbons, each R? is an independently selected unsubstituted linear or branched alkyl group having from 1 to 10 carbons, m is an integer from 1 to 11, and n is an integer from 1 to 11, in the presence of a rare earth catalyst and a cocatalyst under conditions to induce a heteropolymerization reaction between the unsubstituted oc-olefin and amino-olefin monomers to provide a polar-functionalized poly olefin.

Abstract: A method for evaluating long-term durability of a resin for piping is provided. Unlike the conventional FNCT evaluation method requiring a long period of time, the method disclosed herein is capable of predicting long-term durability of a resin for piping in a short time, by a simple calculation using a content of tie molecules, an entanglement molecular weight (Me) and a content of ultrahigh molecular weight components. In addition, the olefinic polymer is configured to have a predetermined relationship in relation to the content of tie molecules, the entanglement molecular weight (Me) and the content of ultrahigh molecular weight components, whereby the polymer of the present application can be used in the manufacture of a heating pipe requiring excellent long-term durability.

Abstract: To provide a fluorinated elastic copolymer composition such that solubility of a fluorinated elastic copolymer in a solvent is excellent, the solvent is easily removed, and the solvent is easily available. A fluorinated elastic copolymer composition comprising a fluorinated elastic copolymer having units based tetrafluoroethylene and units based on CF2=CFORf1 (wherein Rf1 is a C1-10 perfluoroalkyl group), and a fluorinated solvent having a perfluorohydrocarbon group, wherein the perfluorohydrocarbon group having the largest number of carbon atoms in the fluorinated solvent has from 3 to 7 carbon atoms, the fluorinated solvent has a boiling point of from 50 to 160° C., and the fluorinated solvent has a fluorine atom content (fluorine atom content (mass %)=(19×number of fluorine atoms in the fluorinated solvent/molecular weight of the fluorinated solvent)×100) of from 69 to 80 mass %.

Abstract: A curable composition contains a predetermined compound containing a substituted or unsubstituted acrylamide group and a substituted or unsubstituted acrylate group, and a predetermined compound containing a (meth)acrylamide group or a betaine monomer.

Abstract: A curable composition contains a betaine monomer having a predetermined structure and a polyfunctional (meth)acrylamide compound having a predetermined structure.

Abstract: A modified conjugated diene-based polymer, and more particularly, a modified conjugated diene-based polymer having a unimodal molecular weight distribution curve measured by gel permeation chromatography (GPC), molecular weight distribution (PDI; MWD) of less than 1.7, and a Si content of 100 ppm or more based on weight, and including a repeating unit derived from an aromatic vinyl monomer in an amount of 30 wt % or more, and a rubber composition including the same.

Abstract: A modified conjugated diene-based polymer, and more particularly, a modified conjugated diene-based polymer having a unimodal molecular weight distribution curve measured by gel permeation chromatography (GPC), molecular weight distribution (PDI; MWD) of less than 1.7, and a Si content of 100 ppm or more based on weight, and including a repeating unit derived from an aromatic vinyl monomer in an amount from 15 wt % to less than 30 wt %, and a rubber composition including the same.

Abstract: A preparation method of comb structure temperature/pH-responsive polycarboxylic acid adopts acrylic ester, temperature/pH-responsive monomer and other raw materials to obtain polycarboxylic acid via acrylate monomer self-polymerization, grafting with temperature/pH-responsive monomers and hydrolyzation. In other words, acrylate is used as the reaction monomer to polymerize polyacrylate with controllable molecular weight under the action of initiator and chain transfer agent, then the graft copolymers are copolymerized with temperature/pH-responsive monomers to obtain graft copolymers with acrylate polymers main chain and temperature/pH-responsive polymer side chains. Finally, the graft copolymer is hydrolyzed to obtain the comb structure temperature/pH-responsive polycarboxylic acid with polyacrylic acid main chain and temperature/pH-responsive monomer side chain.

Abstract: The present invention relates to a new process for preparing polyisocyanates containing isocyanurate groups and being flocculation-stable in solvents from (cyclo)aliphatic diisocyanates.